Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled DMT Safety and Tolerability in Healthy Adults
NCT05901012Phase 1Completed
- Sponsor
- Universidade Federal do Rio Grande do Norte
- Start
- Apr 2023
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of DMT in major depressive disorder (MDD), sponsored by Universidade Federal do Rio Grande do Norte. Primary endpoints: Systolic Blood Pressure at 2 hours and Diastolic Blood Pressure at 2 hours. Started Apr 2023; status: completed.
02
Drugs
DMT
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05901012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05901012.